Revance Therapeutics, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Revance Therapeutics announced its Q3 2024 financial results, highlighting product revenue growth and strategic shifts, while navigating a pending merger and ongoing operational adjustments.
Revance Therapeutics reports a net loss of $37.5 million for the second quarter of 2024, with revenue growth driven by increased sales of DAXXIFY and RHA dermal fillers.
Revance Therapeutics reports a net loss of $53.2 million for Q1 2024, while seeing a 13% increase in product revenue compared to the same period last year.